Immunocore Holdings plc is a biotechnology company that specializes in developing T-cell receptor-based therapies for the treatment of cancer and other diseases. The company was founded in 2008 and is headquartered in Oxfordshire, United Kingdom. Immunocore’s technology platform is based on the use of soluble T-cell receptors (TCRs) that can recognize and bind to specific targets on the surface of cancer cells. This approach allows for highly targeted therapies that can selectively kill cancer cells while sparing healthy cells. Immunocore has a pipeline of product candidates in various stages of development, including IMCgp100, which is being evaluated in clinical trials for the treatment of melanoma. The company has partnerships with several pharmaceutical companies and has raised significant funding from investors to support its research and development efforts.
